Latest Affymetrix Microarray Offers New Users a Cost-effective and Easy-to-use Alternative for Gene-level Expression Profiling
April 03 2007 - 8:00AM
Business Wire
Affymetrix Inc. (NASDAQ: AFFX) today announced the full commercial
launch of the GeneChip� Human Gene 1.0 ST Array, the latest
addition to its whole-transcript assay-based gene expression
product family. The new microarray measures the overall expression
of all transcripts derived from a gene, not just the 3� end of a
gene. As a result, the Human Gene 1.0 ST Array delivers a more
complete and accurate view of a gene�s total transcription activity
compared to traditional expression array designs. The Human Gene
1.0 ST Array is a cost-effective gene expression profiling option
for new microarray users. Its affordable price and simplified
workflow will enable more scientists to incorporate microarray
technology in their research more often. Researchers will also be
able to perform larger expression studies with additional
replicates to gain a more accurate picture of gene activity. The
latest Affymetrix product complements the more comprehensive Human
Exon 1.0 ST Array, which offers both gene-level expression
profiling and alternative splicing analysis in a single experiment.
�The new Human Gene 1.0 ST Array offers the latest available
content at an attractive price point, making it an ideal solution
for researchers with restricted budgets who were not able to work
with Affymetrix technology in the past,� said Shawn Levy, Ph.D.,
assistant professor of biomedical informatics and director of the
Vanderbilt Microarray Shared Resource. �With the gene and exon
arrays on the same WT assay platform, Affymetrix provides a logical
product progression that enables customers to gain an understanding
of the critical roles that gene expression or alternative splicing
play in biology.� In the Human Gene 1.0 ST Array design, each of
the 28,869 genes is represented by a set of approximately 26
probes. This simplified design strategy provides one value from one
probe set for each gene, yielding a more accurate representation of
all of the transcription activities for each gene of interest than
traditional expression array designs. Affymetrix Expression
Console� Software offers additional tools to further simplify the
analysis workflow, making it as easy to interpret gene-level
expression on Human Gene 1.0 ST Arrays as 3�-based expression
microarrays. �Between the traditional 3� U133 Array, the
new-generation Human Exon 1.0 ST Array and now the Human Gene 1.0
ST Array, Affymetrix has the most complete portfolio of gene
expression products to meet the growing and diverging customer
demands,� said Sean George, vice president of the academic business
unit at Affymetrix. �The new Human Gene 1.0 ST Array complements
the Human Exon 1.0 ST Array, offering an additional choice for new
microarray users on the gold-standard microarray platform at a very
affordable price. This product is a direct result of Affymetrix�
continued innovation and dedication to making larger-scale genomic
studies more economical.� The Affymetrix Human Gene 1.0 ST Array
utilizes the same GeneChip technology that has been the industry
standard in microarray research for the past decade.�More than
1,500 systems have been shipped around the world and the technology
has generated data for more than 8,500 peer-reviewed scientific
publications. The complete system includes flexible
instrumentation, proven GeneChip microarrays, optimized assays and
reagents, as well as open software architecture. For more
information on recent discoveries using Affymetrix whole-transcript
gene expression products, please visit: Researchers Discover
Expression Profiles with Distinct Splice Variants that Improves
Glial Tumor Classification
http://www.microarraybulletin.com/community/article.php?p=226
Researchers Investigate Variation in Alternative Splicing in a
Human Population
http://microarraybulletin.com/community/article.php?p=257 Gene
Expression Analysis on Exon Arrays Provides High-sensitivity
Results
http://www.microarraybulletin.com/community/article.php?p=258 Gene
Expression Summaries and Detection of Alternative Splicing
http://www.microarraybulletin.com/community/article.php?p=256 For
more information on the Affymetrix Human Gene 1.0 ST Array, please
visit: http://www.affymetrix.com/genechip/genearray.affx. About
Affymetrix Affymetrix GeneChip� microarray technology is the
industry-standard tool for analyzing complex genetic information.
After inventing microarray technology in the late 1980s, Affymetrix
scientists have been dedicated to developing innovative products
that provide researchers with a more complete view of the genome.
These products continue to accelerate genetic research and enable
scientists to develop diagnostics and tailor treatments for
individual patients by identifying and measuring the genetic
information associated with complex diseases. Today, Affymetrix
technology is used by the world�s top pharmaceutical, diagnostic
and biotechnology companies, as well as leading academic,
government and not-for-profit research institutes. More than 1,500
systems have been shipped around the world and more than 8,500
peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Sacramento, Calif., and Singapore. The
company has about 1,100 employees worldwide and maintains sales and
distribution operations across Europe and Asia. For more
information about Affymetrix, please visit the company�s website at
www.affymetrix.com. Forward-looking Statements All statements in
this press release that are not historical are �forward-looking
statements� within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix�
�expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties associated with the success of the Affymetrix Human
Gene 1.0 ST Array discussed in this press release; risks of the
company�s ability to achieve and sustain higher levels of revenue,
higher gross margins and reduced operating expenses; uncertainties
relating to technological approaches, manufacturing and product
development; personnel retention; uncertainties related to cost and
pricing of Affymetrix products; dependence on collaborative
partners; uncertainties relating to sole-source suppliers;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix� Form 10-K for the
year ended December 31, 2006, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix�
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024